Compare JAKK & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAKK | IKT |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.2M | 240.1M |
| IPO Year | 1996 | 2020 |
| Metric | JAKK | IKT |
|---|---|---|
| Price | $20.26 | $1.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $35.00 | $5.00 |
| AVG Volume (30 Days) | 62.2K | ★ 1.3M |
| Earning Date | 04-28-2026 | 03-26-2026 |
| Dividend Yield | ★ 4.96% | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $331,249,000.00 | N/A |
| Revenue This Year | $9.46 | N/A |
| Revenue Next Year | $4.36 | $33.33 |
| P/E Ratio | $23.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.87 | $1.33 |
| 52 Week High | $23.25 | $2.37 |
| Indicator | JAKK | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 50.86 |
| Support Level | $19.16 | $1.77 |
| Resistance Level | $21.06 | $1.88 |
| Average True Range (ATR) | 0.74 | 0.12 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 59.55 | 46.94 |
Jakks Pacific Inc is a multi-product line, multi-brand toy company that designs, produces, markets, sells, and distributes toys and related kid-targeted consumer products, including kids' indoor and outdoor furniture, costumes, and various product lines in the sporting goods and home furnishings space. Its product offerings include Traditional toys and electronics such as Action figures, Toy vehicles, Dolls and accessories, Ride-on toys, Toys for pets, and others. The company's products have been divided into two segments: Toys/Consumer Products and Costumes. It generates the majority of its revenue from the Toys/Consumer Products segment.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.